Europharma, leading developers of complete fish health and welfare programmes, has appointed a new Analytical Services Manager, bringing with her four years of experience in aquaculture to the organisation.
Dr Anna Kintner began working at Europharma this summer following completion of her PhD in Marine Biology at St Andrews University. Anna’s initial research focused on Australian box jellyfish venom toxicology, and she moved on to a PhD in Scotland in 2012 studying jellyfish population dynamics and their effects on salmon health.
During this time, Anna often used Europharma’s laboratory facilities to gain vital industry experience and collect data, whilst building relationships with the team.
Anna is now working at the Europharma HQ in Clydebank, splitting her time between carrying out analyses in the lab and engaging with customers across Scotland to ensure they are getting the best results out of their fish health and welfare programmes.
“I am thrilled to have taken up the role as Analytical Services Manager at Europharma. I first met Nikos Steiropoulos and the rest of the team whilst I was studying for my PhD at St Andrews University so when the job came up, it was a fantastic fit.
“In this field, you need to be ready to learn and create new techniques and solutions all the time, and work with to customers to make sure you’re addressing their needs. I love that the job always brings new opportunities for innovation.
“It’s a great balance where I have my own lab to meet customers’ needs whilst still being able to investigate new technological avenues.”
Over the next year, one of Anna’s key priorities will be SuperSmolt ATPase Analysis. SuperSmolt is a unique feed programme for hatcheries that offers optimal smoltification of Atlantic salmon without any need for a winter photoperiod.
Nikos Steiropoulos, CEO of Europharma UK, added:
“We are delighted to welcome Anna to the team here at Europharma. Anna has a great breadth of experience and our paths have crossed on many occasions over the years during her studies, so it is a great pleasure to continue working with her. It’s an exciting time for us with a busy year ahead as the transition of the current ATPase analysis method onto a PCR ATPase biomarkers method already used in Europharma Norway – will also be one of the internal development projects that Anna is going to help us with.
“We look forward to supporting Anna’s progression within our team.”